author-photo

C. Dittrich

European Organisation for Research and Treatment of Cancer

11

Papers

391

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

2008 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (26)
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG

2007 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (40)
Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

2007 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (87)
Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study

2005 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (19)
Imatinib mesylate (Glivec) dans les glioblastomes récidivants. Résultats de la Phase II multicentrique EORTC : NDDG/BTG

2005 Neurochirurgie
Show All
- Source
- Cite
- Save
Citations (1)
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck: An EORTC New Drug Development Group Study

2004 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (41)
Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study

2004 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (89)
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.

2003 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (27)
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme

2002 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (31)
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

2002 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (22)